Thursday, 21 February, 2019

Juno Therapeutics Inc (JUNO) CEO Hans Edgar Bishop Sells 270250 Shares

Picking Up       Deal volume in U.S. biotechnology so far this quarter is at the highest since 2010              Data compiled by Bloomberg Picking Up Deal volume in U.S. biotechnology so far this quarter is at the highest since 2010 Data compiled by Bloomberg
Nellie Chapman | 23 January, 2018, 00:57

Citigroup cut shares of Juno Therapeutics (NASDAQ:JUNO) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, reports. Zacks Investment Research downgraded shares of Juno Therapeutics from a hold rating to a sell rating in a report on Wednesday. Trading volume for Juno Therapeutics Inc. was 8.44 Million in its previous trading session. The stock tapped a 52-week high of US$3.25 while the mean 12-month price target for the shares is US$3.67. Separately, on January 18, Maxim's Jason McCarthy assigned a Buy rating to the stock and has a price target of $98. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". The company now has an average rating of "Hold" and an average target price of $47.26. Capital International Sarl who had been investing in Netease Inc Adr for a number of months, seems to be bullish on the $42.73 billion market cap company. JUNO's latest closing price was 82.13% away from the average price of 200 days while it maintained a distance of 28.90% from the 50 Day Moving Average and 37.05% away compared to its SMA 20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. The stock of Juno Therapeutics, Inc.

The Wall Street Journal reported last week the two companies were in deal talks. The firm had revenue of $44.80 million during the quarter, compared to analysts' expectations of $18.12 million. According to their observations and findings, the stock could provide a high EPS of $-0.59/share and a low EPS of $-1.59/share. This downside isn't anything new for Celgene shares, which have shed roughly 26% in the past six months, and recent resistance forming at the stock's 60-day trendline. On a consensus basis, analysts have given a recommendation of 2.30 on company shares. Also, Director Richard Klausner sold 36,000 shares of the stock in a transaction on Thursday, December 21st.

Celgene already owns approximately a stake of around 9.7% in Juno. The disclosure for this sale can be found here.

David Nierengarten, head of health-care equity research at Wedbush, told CNBC, "Celgene has a big revenue hole to fill over the next few years" and Juno's treatment could potentially "fill that gap". The stock increased 1.04% or $3.36 during the last trading session, reaching $325.55. It also increased its holding in Omeros Corp (NASDAQ:OMER) by 400,000 shares in the quarter, for a total of 1.70M shares, and has risen its stake in Mersana Therapeutics. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company's stock valued at $128,357,000 after purchasing an additional 110,503 shares during the last quarter. Finally, Capital World Investors boosted its position in shares of Juno Therapeutics by 13.8% during the 2nd quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company's stock worth $684,000 after purchasing an additional 1,328 shares during the last quarter. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders.